Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.

Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S, Sershen H, Lajtha A.

Schizophr Res. 2009 May;110(1-3):149-55. doi: 10.1016/j.schres.2009.02.001. Epub 2009 Feb 28.

PMID:
19251401
2.

Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A.

Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.

3.

Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia.

Liu ME, Tsai SJ, Jeang SY, Peng SL, Wu SL, Chen MC, Tsai YL, Yang ST.

Psychiatry Res. 2011 Nov 30;190(1):79-84. doi: 10.1016/j.psychres.2011.04.018. Epub 2011 Jun 1.

PMID:
21636135
4.

Varenicline modulates spatial working memory deficits in smokers with schizophrenia.

Wing VC, Wass CE, Bacher I, Rabin RA, George TP.

Schizophr Res. 2013 Sep;149(1-3):190-1. doi: 10.1016/j.schres.2013.06.032. Epub 2013 Jul 11. No abstract available.

PMID:
23849883
5.

A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.

Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, George TP.

J Clin Psychiatry. 2012 May;73(5):654-60. doi: 10.4088/JCP.11m07522. Erratum in: J Clin Psychiatry. 2012 Jul;73(7):1035.

PMID:
22697191
6.

Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study.

Fatemi SH, Yousefi MK, Kneeland RE, Liesch SB, Folsom TD, Thuras PD.

Schizophr Res. 2013 May;146(1-3):376-8. doi: 10.1016/j.schres.2013.02.015. Epub 2013 Mar 16. No abstract available.

PMID:
23507358
7.

Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies.

Cerimele JM, Durango A.

J Clin Psychiatry. 2012 Aug;73(8):e1039-47. doi: 10.4088/JCP.11r07410. Review.

PMID:
22967780
8.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
9.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
10.

Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.

Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL.

Neuropsychopharmacology. 2012 Feb;37(3):660-8. doi: 10.1038/npp.2011.238. Epub 2011 Nov 2.

11.

Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.

Roh S, Hoeppner SS, Schoenfeld D, Fullerton CA, Stoeckel LE, Evins AE.

Psychopharmacology (Berl). 2014 Feb;231(4):765-75. doi: 10.1007/s00213-013-3286-3. Epub 2013 Oct 11.

12.

Varenicline augmentation in depressed smokers: an 8-week, open-label study.

Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH.

J Clin Psychiatry. 2009 Jul;70(7):1026-31. Epub 2009 Mar 24.

13.

Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity.

Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, Evins AE.

Psychopharmacology (Berl). 2012 Jan;219(1):25-34. doi: 10.1007/s00213-011-2373-6. Epub 2011 Jun 22.

14.

The effects of varenicline on attention and inhibitory control among treatment-seeking smokers.

Rhodes JD, Hawk LW Jr, Ashare RL, Schlienz NJ, Mahoney MC.

Psychopharmacology (Berl). 2012 Sep;223(2):131-8. doi: 10.1007/s00213-012-2700-6. Epub 2012 Apr 12.

PMID:
22526531
15.

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.

Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, Sershen H, Li C, Ren J, Liu Y, Youseff M, Lajtha A, Guidotti A, Weiser M, Davis JM.

PLoS One. 2016 Jan 5;11(1):e0143490. doi: 10.1371/journal.pone.0143490. eCollection 2016.

16.

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.

J Clin Psychiatry. 2008 Feb;69(2):274-85.

PMID:
18232726
17.

Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.

Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA.

JAMA. 2014 Jan 8;311(2):145-54. doi: 10.1001/jama.2013.285113.

18.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD006103.

PMID:
18646137
19.

Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.

Ashare RL, McKee SA.

Exp Clin Psychopharmacol. 2012 Feb;20(1):63-70. doi: 10.1037/a0025594. Epub 2011 Sep 26.

20.

Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia.

Smith RC, Singh A, Infante M, Khandat A, Kloos A.

Neuropsychopharmacology. 2002 Sep;27(3):479-97.

Items per page

Supplemental Content

Write to the Help Desk